BENITEC BIOPHAR/S (NASDAQ:BNTC) Sees Significant Increase in Short Interest

BENITEC BIOPHAR/S (NASDAQ:BNTC) was the target of a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 5,200 shares, a growth of 44.4% from the June 30th total of 3,600 shares. Currently, 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 33,100 shares, the days-to-cover ratio is currently 0.2 days.

An institutional investor recently raised its position in BENITEC BIOPHAR/S stock. Morgan Stanley lifted its stake in BENITEC BIOPHAR/S (NASDAQ:BNTC) by 82.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,690 shares of the biotechnology company’s stock after acquiring an additional 12,934 shares during the period. Morgan Stanley owned approximately 2.68% of BENITEC BIOPHAR/S worth $113,000 at the end of the most recent reporting period. 4.72% of the stock is currently owned by hedge funds and other institutional investors.

Separately, LADENBURG THALM/SH SH began coverage on shares of BENITEC BIOPHAR/S in a research note on Monday, April 20th. They issued a “buy” rating and a $14.00 target price on the stock.

NASDAQ BNTC opened at $7.14 on Friday. The stock has a 50-day simple moving average of $7.73 and a 200 day simple moving average of $6.38. BENITEC BIOPHAR/S has a twelve month low of $4.14 and a twelve month high of $19.80.

BENITEC BIOPHAR/S Company Profile

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.

See Also: What is Blockchain?

Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.